Patents Assigned to Nucleix
-
Patent number: 11952632Abstract: Methods and kits for detection of cancer-related mutations in a DNA sample using enzymatic restriction and real-time PCR. A DNA sample is subjected to digestion with a restriction endonuclease to obtain restriction endonuclease-treated DNA, followed by co-amplification of a restriction locus comprising a cancer mutation site and a control locus. A ratio of signal intensities of the amplification products of the restriction locus and the control locus is used to detect the cancer-related mutation.Type: GrantFiled: January 6, 2019Date of Patent: April 9, 2024Assignee: NUCLEIX LTD.Inventors: Danny Frumkin, Adam Wasserstrom, Revital Knirsh
-
Publication number: 20240093302Abstract: Methods and systems for assessing the presence of cancer in a subject and predicting the tissue source of the cancer are provided, by analyzing DNA methylation markers in cell- free DNA samples, particularly cell-free DNA from plasma samples.Type: ApplicationFiled: January 18, 2022Publication date: March 21, 2024Applicant: NUCLEIX LTD.Inventors: Danny FRUMKIN, Adam WASSERSTROM, Revital KNIRSH
-
Publication number: 20240026453Abstract: Methods and systems for genetic and epigenetic profiling of DNA samples and detecting genetic and epigenetic changes in DNA samples are provided, which involve digestion of DNA with methylation-sensitive restriction enzymes, followed by high-throughput sequencing and analysis of sequence reads. Advantageously, the methods and systems of the present invention are sensitive yet accurate, and enable working with very low amounts of DNA and receive vast amount of information, including methylation data, mutation data and more, based on sequencing data from a single run.Type: ApplicationFiled: November 18, 2021Publication date: January 25, 2024Applicant: NUCLEIX LTD.Inventors: Danny FRUMKIN, Adam WASSERSTROM, Nimrod AXELRAD, Revital KNIRSH
-
Patent number: 11866786Abstract: Methods and kits for identification of lung cancer in a subject based on alterations in DNA methylation at selected genomic loci are provided.Type: GrantFiled: January 17, 2019Date of Patent: January 9, 2024Assignee: NUCLEIX LTD.Inventors: Danny Frumkin, Adam Wasserstrom
-
Publication number: 20240002923Abstract: Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.Type: ApplicationFiled: April 17, 2023Publication date: January 4, 2024Applicant: NUCLEIX LTD.Inventors: Danny FRUMKIN, Adam WASSERSTROM, Revital KNIRSH
-
Publication number: 20230220458Abstract: Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.Type: ApplicationFiled: September 5, 2022Publication date: July 13, 2023Applicant: NUCLEIX LTD.Inventors: Danny Frumkin, Adam Wasserstrom, Revital Knirsh, Orna Savin
-
Patent number: 11629375Abstract: Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.Type: GrantFiled: February 20, 2019Date of Patent: April 18, 2023Assignee: NUCLEIX LTD.Inventors: Danny Frumkin, Adam Wasserstrom, Revital Knirsh
-
Patent number: 11434528Abstract: Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.Type: GrantFiled: March 17, 2020Date of Patent: September 6, 2022Assignee: NUCLEIX LTD.Inventors: Danny Frumkin, Adam Wasserstrom, Revital Knirsh, Orna Savin
-
Patent number: 9783850Abstract: The present disclosure relates to methodology for fast and cost-effective identification of the source of DNA samples. DNA samples obtained from unknown or unrecognized tissues or cell types are analyzed according to the methodology described herein, yielding an identification of the tissue and/or cell type source. Identification is based on sequential biochemical procedures including methylation sensitive/dependent restriction and polymerase chain reaction, followed by analysis of the data. All biochemical steps are performed in a single test tube. The disclosure has immediate applications in forensic science for identification of the tissue source of DNA obtained from biological stains. The disclosure also has immediate applications in cancer diagnosis for identification.Type: GrantFiled: February 17, 2011Date of Patent: October 10, 2017Assignee: NucleixInventors: Danny Frumkin, Adam Wasserstrom
-
Patent number: 9752187Abstract: The present application describes methods for accurate and cost-effective categorization of DNA samples into different types of in vitro generated DNA or different types of natural DNA such as from different tissues and/or physiological/pathological states. The invention achieves categorization by comparing “signal ratios” that are correlated to ratios of methylation levels at specific genomic loci, but does not rely on calculation of actual methylation levels at any genomic locus. Therefore the disclosed inventive method eliminates the requirement for external DNA species and controls, thereby simplifying and increasing the accuracy of the assay. The described inventive technology also enables performing the categorization of DNA together with DNA profiling in the same reaction, thereby allowing for concomitant categorization and determination of identity of the samples.Type: GrantFiled: June 8, 2012Date of Patent: September 5, 2017Assignee: NucleixInventors: Adam Wasserstrom, Danny Frumkin
-
Patent number: 9476100Abstract: Methods and kits for identification of bladder cancer in a subject based on alterations in DNA methylation at selected genomic loci are provided.Type: GrantFiled: July 6, 2015Date of Patent: October 25, 2016Assignee: Nucleix Ltd.Inventors: Danny Frumkin, Adam Wasserstrom
-
Patent number: 9458503Abstract: The present invention provides methods for distinguishing between natural and artificial DNA in samples containing nucleic acid molecules. In addition, the present invention provides methods for verifying that DNA profiles obtained from samples represent natural DNA. In various embodiments, the methods employ an array of nucleic acid based procedures for verifying that a DNA sample originates from a natural source. The invention further provides kits for verifying that a DNA sample originates from a natural source employing the methods and reagents described in the disclosure.Type: GrantFiled: July 1, 2010Date of Patent: October 4, 2016Assignee: NucleixInventors: Adam Wasserstrom, Danny Frumkin
-
Publication number: 20130084571Abstract: The present disclosure relates to methodology for fast and cost-effective identification of the source of DNA samples. DNA samples obtained from unknown or unrecognized tissues or cell types are analyzed according to the methodology described herein, yielding an identification of the tissue and/or cell type source. Identification is based on sequential biochemical procedures including methylation sensitive/dependent restriction and polymerase chain reaction, followed by analysis of the data. All biochemical steps are performed in a single test tube. The disclosure has immediate applications in forensic science for identification of the tissue source of DNA obtained from biological stains. The disclosure also has immediate applications in cancer diagnosis for identification.Type: ApplicationFiled: April 19, 2011Publication date: April 4, 2013Applicant: NucleixInventors: Adam Wasserstrom, Dan Frumkin